American journal of otolaryngology · 2025
Effect of corticosteroid-based combination therapy on sudden deafness: a retrospective study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhi Liang'e, Li Shiyuan, Feng Yajin, Liu Qian, Jiang Zhendong, Zhong Cheng, He Ya
Аннотация
OBJECTIVES: Systemic corticosteroid therapy is widely recommended as the first-line treatment for sudden deafness(SD). However, the factors influencing treatment outcomes remain uncertain, and the efficacy of corticosteroid-based combination therapies is still controversial. Aim of this study is to declare the impact of treatment initiation time, patient age and evaluate the combined therapies including hyperbaric oxygen therapy (HBOT), batroxobin, and acupuncture on treatment outcome.
METHODS: 248 SD patients undergoing corticosteroid-based combination therapy were included and classified into four subtypes. Additionally, 17 patients who received remedial intratympanic corticosteroid (ICT) were analyzed. Improvement of hearing and accompanying symptoms (vertigo/tinnitus) was evaluated to indicate the effectiveness of treatment.
RESULTS: Early-stage treatment (≤7 days) and younger patients (<18 years) were associated with better outcomes(P < 0.05). For combined therapies, batroxobin and acupuncture showed no significant effect on treatment outcomes(P > 0.05). In contrast, patients receiving HBOT exhibited worse hearing improvement in total deafness and low-frequency descending subtypes(P < 0.05).
CONCLUSIONS: Early-stage treatment should be emphasized for patients with SD, particularly in young patients. Combined therapies, especially HBOT, cannot improve prognosis. Remedial ICT can further improved outcomes in SD patients with total deafness subtype who responded poorly to systemic corticosteroid therapy.
METHODS: 248 SD patients undergoing corticosteroid-based combination therapy were included and classified into four subtypes. Additionally, 17 patients who received remedial intratympanic corticosteroid (ICT) were analyzed. Improvement of hearing and accompanying symptoms (vertigo/tinnitus) was evaluated to indicate the effectiveness of treatment.
RESULTS: Early-stage treatment (≤7 days) and younger patients (<18 years) were associated with better outcomes(P < 0.05). For combined therapies, batroxobin and acupuncture showed no significant effect on treatment outcomes(P > 0.05). In contrast, patients receiving HBOT exhibited worse hearing improvement in total deafness and low-frequency descending subtypes(P < 0.05).
CONCLUSIONS: Early-stage treatment should be emphasized for patients with SD, particularly in young patients. Combined therapies, especially HBOT, cannot improve prognosis. Remedial ICT can further improved outcomes in SD patients with total deafness subtype who responded poorly to systemic corticosteroid therapy.